Education
About Us
Working with TipRanks
Follow Us
Neurogene (NGNE)
NASDAQ:NGNE
NGNE Stock Chart & Stats
Day’s Range― - ―
52-Week Range$6.88 - $74.49
Previous CloseN/A
Volume20.02K
Average Volume (3M)313.83K
Market Cap
$163.87M
Enterprise Value$39.60M
Total Cash (Recent Filing)$32.30M
Total Debt (Recent Filing)$47.00K
Price to Earnings (P/E)―
Beta2.46
Next Earnings
May 09, 2025EPS Estimate
-1.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.60
Shares Outstanding14,262,066
10 Day Avg. Volume421,772
30 Day Avg. Volume313,826
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)228.20
Price to Cash Flow (P/CF)-3.40
P/FCF Ratio0.00
Enterprise Value/Market Cap0.24
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit42.81
Enterprise Value/Ebitda-0.55
Forecast
1Y Price Target
$44.40Price Target Upside269.38% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
---
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentNGN-401 has shown impressive efficacy and a tolerable safety profile.
Financial StabilityNeurogene has sufficient cash to provide a runway extending through the NGN-401 pivotal trial.
Regulatory DesignationNGN-401 has received Priority Medicines (PRIME) designation by the European Medicines Agency (EMA).
Bears Say
Adverse EventsHigh-dose NGN-401 led to treatment-related serious adverse events and other high-dose patients experienced Grade 2 and 3 treatment-emergent adverse events.
Clinical RisksRisks include potential delays in advancing candidates and the possibility of not generating favorable clinical data, particularly for NGN-401 in Rett syndrome.
---
Ownership Overview
14.83% Insiders
11.57% Mutual Funds
0.36% Other Institutional Investors
66.70% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
NGNE FAQ
What was Neurogene’s price range in the past 12 months?
Neurogene lowest stock price was $6.88 and its highest was $74.49 in the past 12 months.
What is Neurogene’s market cap?
Neurogene’s market cap is $163.87M.
When is Neurogene’s upcoming earnings report date?
Neurogene’s upcoming earnings report date is May 09, 2025 which is in 17 days.
How were Neurogene’s earnings last quarter?
Neurogene released its earnings results on Mar 24, 2025. The company reported -$1 earnings per share for the quarter, beating the consensus estimate of -$1.129 by $0.129.
Is Neurogene overvalued?
According to Wall Street analysts Neurogene’s price is currently Undervalued.
Does Neurogene pay dividends?
Neurogene does not currently pay dividends.
What is Neurogene’s EPS estimate?
Neurogene’s EPS estimate is -1.05.
How many shares outstanding does Neurogene have?
Neurogene has 14,262,066 shares outstanding.
What happened to Neurogene’s price movement after its last earnings report?
Neurogene reported an EPS of -$1 in its last earnings report, beating expectations of -$1.129. Following the earnings report the stock price went up 1.719%.
Which hedge fund is a major shareholder of Neurogene?
Currently, no hedge funds are holding shares in NGNE
---
Neurogene Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$44.40 (269.38% Upside)
$44.40 (269.38% Upside)
Blogger Sentiment
Bullish
NGNE Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 597.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $76.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.3%
Last 30 Days ▲ 12.0%
Last 30 Days ▲ 12.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-60.57%
12-Months-Change
Fundamentals
Return on Equity
-30.28%
Trailing 12-Months
Asset Growth
51.16%
Trailing 12-Months
Company Description
Neurogene
Neurogene Inc. develops life-changing genetic medicines for patients and their families affected by neurological diseases. Its product candidate includes NGN-401, an investigational AAV9 gene therapy for the treatment of Rett syndrome; and NGN-101 to treat neuronal ceroid lipofuscinosis subtype 5 batten disease. The company is headquartered in New York, New York.
---
NGNE Stock 12 Month Forecast
Average Price Target
$44.40
▲(269.38% Upside)
Technical Analysis
ProQR
―
Korro Bio
―
Inhibikase Therapeutics
―
4D Molecular Therapeutics
―
Lyell Immunopharma
―
Best Analysts Covering NGNE
1 Year
1 Year Success Rate
4/11 ratings generated profit
1 Year Average Return
-9.59%
reiterated a buy rating 28 days ago
Copying Paul Matteis's trades and holding each position for 1 Year would result in 36.36% of your transactions generating a profit, with an average return of -9.59% per trade.
---